Bronchitis

Respiratory
2
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 2 programs with unclassified modality

Competitive Landscape

2 companies ranked by most advanced pipeline stage

OD
2 programs
1
1
levofloxacin, azithromycin, amoxicillin/clavulanatePhase 3
levofloxacinPhase 2/3Small Molecule
Roche
RocheSTAVANGER NORWAY, Norway
1 program
GuaifenesinN/A1 trial
Active Trials
NCT02902640Completed52Est. Jul 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
RocheGuaifenesin

Clinical Trials (1)

Total enrollment: 52 patients across 1 trials

NCT02902640RocheGuaifenesin

A Non-Interventional Safety Study of Balsamic Bactrim

Start: Nov 2016Est. completion: Jul 201752 patients
N/ACompleted

Related Jobs in Respiratory

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space